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Summary: Achievement of appropriate precision is a major challenge for the clinical laboratory, particularly
in specialized fields such as enzymology and immunochemistry. Especially in immunochemistry, where accuracy
can only poorly be checked because of a lack of reference methods and a multitude of detectable epitopes,
precision remains an important index of quality. In immunochemical methods there are three main sources
of variation: differences in methodology, lot-to-lot variation and performance of the assay, the latter including
the skill of the technicians and instrument performance. The results of a European Quality Control Programme
for the users of one type of automated immunoassay analyser were compared with a similar Italian Quality
Control Programme for users of different immunometric techniques. The precisions (%CV) of the two
programmes were compared, as well as the number of values lying within one half of the biological variation
of the analysed serum components. Feedback between users and manufacturers leads to a clear improvement
in analysis performance, so that most of the considered values come to lie within the acceptable limits of l/2
of the biological variation. It is concluded that both national and international quality control programmes
are very useful for indicating the intrinsic quality of the quantities used in the clinical laboratory.
Introduction .„ . „,, . . . - , .
 r ,. .dilations. This is mainly a problem of radioim-
The achievement of appropriate precision is a major munoassays, which must use relatively small
challenge for the clinical laboratory today. This ap- batches due to their limited shelf-life;
plies to general clinical chemistry, and to more spe-
cialized fields, such as enzymology and immunochem- 3· the performance of the method/reagents used,
istry. In immunochemistry accuracy can only poorly which are a result of the intrinsic performance of
be checked because of a lack of internationally ac- the technology, the skill of the laboratory techni-
cepted reference methods and because a multitude of cians and the precision of the instruments used,
epitopes i s detected by different commercially avail- . , . . , , ,
able tests. Therefore precision remains an important The <*ove considerations imply that when the preci-
index of quality in this field. Slon of an '"imunoassay » to be enhanced, this can
best be done when manufacturers collaborate with
At the moment, the precision of immunoassays is still the users of their reagents and or instruments. With
less than that of other clinical chemical methods, regard to the different causes of imprecision, the fol-
Three main sources can be found for this variation: lowing can be said.
1. the difference in technique, arising from the use of
 4 AU, , ..- A . . , . * *u ·
,. . . ., -. j j. , + 1- Although differences in techniques are not the im-distmctive antibodies and adjuvent reagents; ™ΑΛ:Λ*Α «»«^„VUT* r *u r *mediate responsibility of the manufacturer, mter-
2. the imprecision of the reagents, which is related to national organisations can play an important co-
lot-to-lot variations, and between/within run os- ordinating role.
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2. Lot-to-lot variations can be reduced by producing
larger batches and by using non-isotopic reagents
with longer shelf-lifes.
3. Performances can be improved by efficient feed-
back between user and manufacturer.
On the other hand, the concentration of serum con-
stituents in human beings is subject to individual
variations (1 —3). In the seventies, when only isotopic
tests with high variations were available, authors
started to consider the combination of biological and
analytical variation (1-6). Thus, one of the goals of
an immunoassay should be to reduce the variation of
a measured value to !/2 of the biological variation
(!/2 BV), and to reduce it sufficiently for the needs of
medical decision making (7).
At the end of 1989 and the beginning of 1990, Eu-
rogenetics N. V., Tessenderlo, Belgium, introduced to
the European market two automated enzyme immu-
noassay analysers, the AIA-1200 and the AIA-600,
produced, together with the reagents to run on them,
by the Tosoh Corporation, Tokyo, Japan.
At the beginning of 1991, Eurogenetics started with
a European Quality Control Programme for all users
of these instruments. The aim was to keep the ana-
lytical variation of the analyses as low as possible.
This article will review the results of the first 6 runs
of this Quality Control Programme (over a time span
of 12 months), and for reference purposes it will
compare them with the results of the national Italian
QC Programme, which uses the same type of samples
at the same frequency and with the same statistical
data reduction (10).
Methods
The ΑΙΑ-instruments are based on the random accessibility
concept, established through the standardization of procedures
and the re-use of the calibration curves, and on the walk-away
automation principle based on the minimization of manual
intervention. As a tool to reduce analytical variation, the above
mentioned Quality Control Programme was initiated. It is su-
pervised by an independent international committee (with mem-
bers from Italy, The Netherlands, France and Belgium).
The Quality Control Programme is an external quality survey
incorporating ΑΙΑ-users from all over Europe. This external
quality control programme, meant as a link between the users,
is organized in the same way as most national quality control
programmes (8, 9). Lyophilized pooled serum samples are ob-
tained from Technostandard, Brescia, Italy. The participants
are supplied with a set of 9 of these sera (comprising three
concentrations each of thyroid, fertility and tumour markers),
mailed at room temperature. Over a period of 12 months, 6
pools of human serum are distributed, each pool being pre-
sented maximally 3 or 4 times, and in random combination
with the others. The participants can therefore never know or
guess the target concentrations of the samples. The same source
of samples and the same distribution procedure was used in the
Italian national QC Programme (10).
Participants performed the assays on their ΑΙΑ-instrument and
returned the results to their local Eurogenetics office or dealer,
identifying the reagent lot numbers and the date of the last
calibration, with a view to explaining any outliers that might
occur.
The collected results were computer-processed, following the
methods described by Pilo et al. (10). Briefly, the consensus
mean, calculated from all the results after outlier rejection, is
implicitly indicated to the participants as a target. The rejection
of outliers is performed according to the method ofHealy (11),
and applied to the distribution of all results, using a symmetrical
5% trimming. Comparison of the deviation of the result pro-
duced by each laboratory (% deviation from the consensus
mean) with the spread of all results (%CV) allows the evalua-
tion of the acceptability of the analytical performance. A report
containing this information is sent back to all participating
laboratories.
Statistical significances in table 1 were calculated using the
mean of the differences at p < 0.5 (12).
Results and Comments
The first run was started in May 1991. By now (Jan-
uary 1993), 8 runs have been performed. The same
sample pool was presented repeatedly during a one
year period (May 1991 to April 1992), and it-vwas
observed that the variation of the consensus means is
smaller than the analytical variation of the respective
value.
In table 1 we have summarized the first 6 runs of the
external Quality Control Programme.
Thyroid markers
Thyrotropin: for sample 1, the %CV decreases signif-
icantly between run 2 and run 6, between run 4 and
run 6 and between run 5 and run 6. For samples 2, 3
and 4 there are no significant changes of %CV. For
sample 5 there is a significant decrease in %CV be-
tween run 1 and run 3, and between run 1 and run
5, but not between run 3 and run 5 (increase not
significant). For sample 6 the %CV increases between
run 2 and run 3.
Tr odothyronine: there are no statistical differences.
Thyroxine: there are no significant differences for
samples 1 and 6. In sample 2, the %CV increases
significantly between runs 1 and 3, but not between
runs 1 and 5. For sample 3, a significant decrease
occurs between runs 2 and 6. In sample 4, a significant
increase exists between runs 1 and 4. For sample 5
the %CV decreases between fun 1 and 5, and between
run 3 and 5, but not between runs 1 and 3.
Fertility markers
Lutropin: there are no shifta for samples 2, 3 and 6.
Sample 1 differs significantly in %CV between runs
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2 and 3 (increase) and between runs 3 and 5 (decrease).
For sample 4, the %CV increases between run 1 and
6, and between runs 4 and 6. In sample 5, the %CV
decreases between runs 1 and 6, but increases between
runs 4 and 6.
Foil i tropin: for sample 1, the %CV increases between
runs 2 and 3. The %CV for sample 2 decreases be-
tween runs 1 and 3, and between runs 1 and 5. For
sample 3, there is an increase in %CV between runs
2 and 3, and between runs 2 and 4, but no significant
difference between runs 3 and 4. Sample 4 shows no
differences. The %CV for sample 5 decreases between
runs 1 and 4, 1 and 6, but not between 4 and 6. The
%CV for sample 6 increases between runs 2 and 5,
but not between 2 and 6. Between runs 5 and 6, there
is a significant decrease.
Prolactin: no differences can be observed.
Tumour markers
oi-Foetoprotein: a very significant decrease in %CV
can be seen in all combinations for all 6 samples from
run 1 to run 6. Only sample 6 shows an increase in
%CV between runs 4 and 6.
Carcinoembryonic antigen: sample 1 shows decrease
in %CV between runs 2 and 6 and between runs 3
and 6, but not between 2 and 3. The %CV for sample
2 decreases from runs 1 to 4 and from 1 to 5. For
samples 3, the consensus mean tends to decline, while
the %CV decreases from run 1 to runs 3, 5 and 6.
Between runs 3 and 5, the %CV increases, but be-
tween runs 5 and 6 it decreases, while no significant
difference is seen between runs 2 and 6. Sample 4
shows no significant differences. Sample 5 shows a
decrease in %CV between runs 2 and 3, but an in-
crease between runs 2 and 5, and 3 and 5. Sample 6
shows a decrease in %CV between runs 2 and 4 and
between runs 4 and 6.
Ferritin: no differences occur for samples 1 and 2.
Sample 3 shows an increased %CV between runs 1
and 3, and between runs 3 and 6, but not between
runs 1 and 6. Sample 5 shows a decrease in %CV
from run 2 to run 3 and from run 2 to run 5. There
is a concentration shift for sample 6, run 6, but no
significant change in %CV.
Human ß-chorionic gonadotropin: The %CV decreases
in samples 1 and 2, but increases in sample 3 (from
runs 3 to 5 and from runs 3 to 6). In sample 4, it
decreases again from run 1 to run 4. The %CV for
sample 5 decreases from run 2 to run 5, but increases
from runs 3 to 5. Sample 6 shows a decrease in %CV
from runs 2 to 6. From run 4 to run 6 there is a
concentration increase.
It can be concluded that the CV of some analytes was
relatively high during run 1 and run 2, but decreased
afterwards, as can be seen for e. g. thyrotropin, folli-
tropin, oc-foetoprotein, Carcinoembryonic antigen and
human ß-chorionic gonadotropin. The decrease in CV
is not so apparent for thyroxine, lutropin and ferritin,
and even absent for triiodothyronine and prolactin.
After runs 5 and 6 the CV's tend to stabilize.
After the 1st and the 2nd run, the international com-
mittee advised Eurogenetics to give certain instruc-
tions to the users. These were related to:
1. rinsing the wash probes more accurately;
2. replacing the wash probes after 2000 tests; and
3. rinsing the substrate container and tubings with
ethanol.
Moreover, in a few cases, after consulting the users,
a service intervention was made. In one case an in-
strument was even replaced.
In our view, the company, in taking this action, cor-
rectly carried out the advice of the committee, as can
be seen in the evolution of the CV during the subse-
quent runs (tab. 1).
Also, towards the end of the observed period, larger
batches of reagents were produced.
As stated in the introduction, the acceptability criteria
for the analytical variation should be equal or lower
than !/2 of the biological variation (1A BV). This quan-
tity includes a measure of the intra-individual varia-
tion and the analytical variation (2, 7, 13 — 22). As
can be seen in table 1, the analytical variations for
thyrotropin, follitropin, prolactin, oc-foetoprotein and
ferritin are acceptable when compared with the 1A BV.
Carcinoembryonic antigen is almost in line, while
triiodothyroinine, thyroxine and lutropin still need
some adjustment. For human ß-chorionic gonadotro-
pin, no data on 1A BV were available in the literature.
Table 2 shows the comparison between the mean
%CV of the Eurogenetics Quality Control Pro-
gramme over the 6 first runs, and the mean %CV of
the Italian National Quality Assurance Programme
which uses the same samples and statistics as the
Eurogenetics QC Programme. The CV given for the
and the other techniques is the mean as calcu-
lated from the European Quality Control Programme
and from the Italian National QC Programme, re-
spectively.
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From table 2, it can be concluded:
Thyroid markers
The reagents for triiodothyroni^e and thyroxine from
almost all companies give variations that are equal
or higher than the 1A BV. The IMX method is clearly
superior to the others for these quantities. For thy-
rotropin, one sees that the non-isotopic methods show
a much lower CV than the isotopic ones.
Fertility markers
For lutropin, the IMX and ΑΙΑ give the lowest CV
values, but there is still room for improvement with
respect to the 1A BV. For follitropin, the AIA-method
gives an average quality. Again IMX is the best one,
while Boehringer and ΑΙΑ are < 1A BV. Generally,
all methods have a CV above the 1A BV for lutropin
and approximately equal to the 1A BV for follitropin.
ΑΙΑ, IMX and Serono give almost equivalent values
for prolactin, which are < 1A BV. There is no differ-
ence in the results of isotopic and non-isotopic meth-
ods, except for DPC.
Tumour markers
The ΑΙΑ gives the lowest CV for carcinoembryonic
antigen and α-foetoprotein, and second lowest for
ferritin. Human -chorionic goriadotropin again gives
an average CV. In terms of 1A BV, the AIA-method
is the best for carcinoembryonic antigen and a-foe-
toprotein. No company meets the limits for carci-
noembryonic antigen, but ΑΙΑ is very close.
In general, except for triiodothyronine and thyroxine,
it can be seen that the non-isotopic methods tend to
give lower CV values than the isotopic methods.
As stated in the introduction, there are two main
manufacturer-dependent sources of analytical varia-
tion: lot-to-lot variation and test performance, which
is related in the case of the ΑΙΑ to the instrument
and the reagent quality. Both of these aspects were
taken into consideration by enlarging the batch size,
by an accurate interpretation of the results arid by
advising specific actions to the customers after the
first two runs of the Eurogenetics Quality Control
Programme. As a result, the total %CV decreased
from run 3 onwards. Further adaptations are needed,
however, for some analytes to meet 1A BV specifica-
tions.
Eurogenetics confirmed to us that short term reagent
improvements (for triiodothytonine, thyroxine, lutro-
pin and carcinoembryonic antigen) are imminent.
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Moreover, the Quality Control Programme has been
extended to include more analytes as from 1993, i.e.
insulin, prostate-specific antigen, prostatic acid phos-
phatase, IgE, somatotropin and.free thyroxine. The
observation time for these quantities has been too
short for sound conclusions. The first impression,
however, is that the tendency is the same for these
recent quantities as for the other more extensively
investigated quantities.
We consider it important to participate in a national
Quality Control Programme in order to see how the
methodology one uses is related to that of other
manufacturers. Also, participation in an international
Quality Control Programme with the same method-
ology provides an important overview of the intrinsic
quality of the method used, as long as internationally
accepted reference methods are not available.
We conclude that the organization of a Quality Con-
trol Programme by Eurogenetics for its own appa-
ratus and reagents is a daring, but highly advisable
operation. In the future, every company that com-
mercializes such instruments, should organize an in-
ternational QC Programme.
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